CN1582157A - Rehydrating formulation - Google Patents
Rehydrating formulation Download PDFInfo
- Publication number
- CN1582157A CN1582157A CNA028220102A CN02822010A CN1582157A CN 1582157 A CN1582157 A CN 1582157A CN A028220102 A CNA028220102 A CN A028220102A CN 02822010 A CN02822010 A CN 02822010A CN 1582157 A CN1582157 A CN 1582157A
- Authority
- CN
- China
- Prior art keywords
- aqueous formulation
- concentration
- galactose
- glucose
- arbitrary aforementioned
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pediatric Medicine (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to an aqueous formulation for combating dehydration comprising a low concentration of galactose and a source of sodium ions which is particularly effective in children (e.g. infants). The dehydration is typically a symptom of severe diarrhoea.
Description
The present invention relates to be used to resist the aqueous formulation of dehydration, it comprises low concentration galactose and a kind of source of sodium ions (for example sodium salt).
Exist many main bodys may be dewatered and the relevant shortage such as the situation of rock salt loss.For example, temper the speed that is used for consuming the fuel reserve of health and increases perspire, it causes the loss of water and rock salt.If if prolong exercise and particularly moderate or higher these losses of ambient temperature can be significant.Other situation that can cause dewatering comprises as the effect of (for example) enterotoxin (for example typically the cholera in the third world), (for example when GI the have a rest when important) result's that has a rest behind virus function (for example typically at the rotavirus of developed world) or the surgical operation excessive temperature, nutritional losses, the heating, suffer from diarrhoea and vomit excessive.Alternatively, the situation that causes dewatering can be self-induced (for example by (alcohol consumption).In egregious cases, fluid and/or electrolytical loss can be clinically important or even dangerous life, particularly in child and old people.
The people can not effectively move when dehydration or when they suffer electrolyte imbalance.The rehydration beverages that comprises inorganic salt and/or high sugar (for example glucose) content is used for a long time to resist these diseases.Yet the administration of glucose can cause the insulin response that amplifies.
Galactose is naturally occurring hexose, for its global needs be insignificant and the application of report seldom.The publication of existing relevant galactose comprises:
(1) the open high energy polysaccharide food of WO-A-01/28360 (Marathade Ltd), it comprises galactose and creatine, is used for motion or opposing hunger or tired;
(2) the open wherein sugared composition of EP-A-0340491 (Biodyn Ag) food that mainly is galactose;
(3) WO-A-96/18313 (University of Nottingham) openly is used to increase the preparation of creatine picked-up, and it comprises creatine, insulin and monosaccharide such as galactose;
(4) (it comprises the galactose that is used for nutritional support and treatment various diseases to WO-A-98/06418 for Mannatech, Inc) open nutritional supplement;
(5) US-A-5843921 (Children's Hospital of Los Angeles) openly is used for the treatment of the preparation of diabetes, and it comprises the monosaccharide that comprises galactose that per unit is less than 3g;
(6) the open sports drink of WO-A-96/08979 (Quadrant Holdings Cambridge Ltd), it comprises trehalose and galactose;
(7) the open sports drink of WO-A-90/02494 (Svenska Mejeriernas Riksforening Ekonomi AB), it comprises the galactose of the milk surum concentrate that derives from desalination and hydrolysis;
(8) EP-A-349712 (Biodyn Ag) openly comprises the food of galactose of the lactose hydrolysis thing form of tooth protection amount; With
(9) EP-A-184121 (Biodyn Ag) openly is used for the anticaries additive of sucrose food, and it comprises galactose I.
The open rehydration sports drink of US-A-5780094 (Marathade Limited), it comprises high concentration galactose and a part of glucose.When the sodium co-transport that is related to high concentration galactose and glucose drove, the absorption of water was efficient and effective in the intestinal.The galactose ratio glucose advantageously influences the water of intestinal picked-up faster.
The present invention is based on understanding and promptly comes effective metabolism galactose and glucose (forming sugar for two of lactose kinds in the milk) in physiological adaptability, uses low concentration galactose child can utilize the effective rehydration of sodium co-transport.Particularly, the rehydration aqueous formulation that the present invention relates to improve, it comprises the dehydration that low concentration galactose and sodium salt are caused by (for example) diarrhoea with opposing.
Therefore from the one hand, the invention provides the aqueous formulation that is used to resist dehydration, it comprises the galactose that concentration is 25-135mM, source of sodium ions and water.
Aqueous formulation of the present invention is more effective in the extreme dehydration of treatment than the ORS that routine contains glucose usually, otherwise extreme dehydration may be fatal to the child.In addition, galactose (not resembling glucose) does not cause initial insulin response.
In preferred embodiments, the galactose concentration in aqueous formulation is 25-130mM, preferred 37-120mM, more preferably 40-120mM, especially preferably 45-90mM.
Source of sodium ions in the aqueous formulation of the present invention typically is sodium salt.The permissible sodium salt of any physiology will meet the demands.Example comprises sodium lactate, sodium chloride, sodium citrate, trisodium citrate, dibastic sodium phosphate (sodium hydrogenphosphate), sodium hydrogen phosphate (disodium hydrogen phosphate) and sodium bicarbonate.It is favourable for the acidosis relevant with the diarrhoea of specific pathogen (for example viral) that counter ion counterionsl gegenions (for example chloride, bicarbonate, phosphate, hydrophosphate or citrate) can provide stability and buffering capacity and sodium citrate.Preferred sodium chloride.
The concentration that can revise sodium ion is to promote replenishing of sodium co-transport and electrolyte losses.In preferred embodiments, the Na ion concentration in the aqueous formulation is 25-100mM, preferred 30-90mM, preferred especially 35-90mM, more preferably 45-90mM, also more preferably 60-90mM.In order to resist dehydration as the symptom of serious diarrhoea (for example causing) by the enterotoxin effect, preferably higher na concn (for example 80-90mM 90mM) according to appointment.In order to resist, preferably hang down na concn as the gentlier dehydration of the symptom of diarrhoea (for example cause or when hypernatronemia (hypernatraemia) is risky) by virus function.
An embodiment of aqueous formulation further comprises one or more other ions (for example potassium, magnesium, calcium or zinc) source advantageously to realize additional as the mineral of (for example) symptom of diarrhea loss.Other ion source typically is salt (for example mineral salt) as chloride.
Preferred aqueous formulation comprises potassium ion source (for example potassium salt such as potassium chloride).Potassium salt is used for electrolyte supplement loss.In preferred embodiments, potassium concentration is 5-35mM in the aqueous formulation, preferred 10-30mM, preferred especially 15-25mM, more preferably from about 20-25mM.
The embodiment of aqueous formulation of the present invention further comprises one or more other sugar.In one embodiment of the invention, one or more other sugar can be to be selected from monosaccharide, disaccharide, but but one or more digestible saccharide digestible saccharide for example of oligosaccharide and polysaccharide.These can be natural or synthetic sugar.For example, one or more other sugar can be selected from glucose, sucrose, dextrose, fructose, lactose and maltose.Preferred other sugar is monosaccharide, preferred especially glucose.Therein in the important situation of the osmolality of aqueous formulation (for example super ooze or etc. when oozing (isomolar) solution and being avoided), maltodextrin or senior oligosaccharide can be used for replacing glucose.
In preferred embodiments, the galactose of aqueous formulation and randomly one or more other sugar exist to be enough to satisfy the total amount that requires for the effective sugar of the sodium co-transport of rehydration.In preferred embodiments, the total concentration of sugar is 50-300mM, preferred 50-200mM, preferred especially 55-175mM, more preferably 60-135mM, especially preferably 90-130mM.
In the preferred embodiment of preparation, galactose and glucose exist to be enough to satisfy the amount that the collaborative sugar that shifts of sodium requires in effective rehydration.Typically the molar concentration ratio of galactose and glucose is 0.6: 1-1: 0.6, preferred 0.8: 1-1: 0.8, preferred especially 0.9: 1-1: 0.9, and more preferably the molar concentration ratio is about 1: 1.
In preferred embodiments, the concentration of glucose in aqueous formulation is 30-135mM, preferred 35-130mM, preferred especially 37-120mM, more preferably 40-100mM, especially preferably 45-80mM.
(for example ooze or isosmotic solution when being avoided super) therein in the important situation of the osmolality of aqueous formulation, maltodextrin or senior oligosaccharide can be preferred for replacing glucose.The concentration that the scope of therefore preferred concentration of glucose can be had the oligosaccharide of suitable chain length satisfies.For example, replace the 60mM glucose, can use the maltodextrin of the average chain length 6 of 10mM.
General preparation can typically have about 1: 2 Na ion concentration: the ratio of sugared concentration, for example Na ion concentration of about 60mM and the galactose and the glucose that exist with the 120mM total concentration.Said preparation is that have a rest after as surgical operation situation that result's the diarrhoea or cause of (for example when GI have a rest when important) dewaters will be effective when being self-induction (for example passing through alcohol consumption) in the situation that causes dewatering.
Can use aqueous formulation of the present invention by any conventional route.Preferred aqueous formulation is suitable for oral administration.For example aqueous formulation can be good to eat, can comprise natural or synthetic flavoring agent such as flavoring agent of fruit (for example Ribes fasciculatum Var Chincsis Maxim, Fructus Fragariae Ananssae, Fructus Mali pumilae, mandarin orange, Fructus Citri Limoniae, Citrus aurantium Linn., Fructus Citri tangerinae or raspberry) or caffeine and sweetener in addition for this reason.
Aqueous formulation of the present invention can comprise the permissible stabilizing agent of physiology as required in addition, antioxidant (for example ascorbic acid) and antiseptic (for example sodium benzoate or sorbic acid).
Dosage depends on dehydration level and experimenter's size and the age usually.Usually be equivalent to or be desirable less times greater than the body fluids loss of actual or expection with the dosage that appropriate intervals is used.Typically the dosage of aqueous formulation is 100-250ml.
Citric acid can be added to aqueous formulation partly or entirely to substitute citrate ion and to be used to cushion purpose (typically keeping pH is 2-6).Be citrate and/or when adding citric acid in sodium or other ionic source, the concentration of citrate ion can be 5-30mM in the aqueous formulation, preferred 10-25mM, preferred especially 10-15mM.Phosphate can be used as alternative buffer agent.
(with optional other ion) when being villaumite, the concentration of chloride ion can be 10-100mM in the aqueous formulation in the sodium source, preferred 30-90mM, more preferably 40-85mM, preferred especially 45-80mM.
In order to resist dehydration as serious symptom of diarrhea, preferred higher chloride concentration (for example 70-80mM 80mM) according to appointment.
Aqueous formulation of the present invention can be an aqueous solution, aqueous dispersion or waterborne suspension, and preferred aqueous formulation is an aqueous solution.Preferred aqueous formulation (for example solution) is the aqueous formulation of reformulating (for example solution).For example, the aqueous formulation of reformulation of the present invention can be by the end user in use the aqueous solvent (for example water) by adding proper volume reformulate from the compositions that comprises galactose and source of sodium ions (with randomly one or more other ion sources and one or more other sugar).
From another point of view, the invention provides and can prepare (for example soluble) to form the compositions of aqueous formulation defined above in water, described compositions comprises galactose, source of sodium ions, randomly other sugar and randomly other ion source.For example, compositions comprises galactose and the source of sodium ions that forms the amount of 25-135mM concentration in the aqueous solvent (for example water) that is enough at designated volume.
Can provide compositions of the present invention with any suitable solid or liquid form.For example, can provide compositions with solid form such as powder (for example effervescive or non-effervescive powder) or tablet form or liquid form such as gel or liquid concentrate form.
From another aspect that also has, the invention provides galactose and source of sodium ions and be used for the 25-135mM aqueous galactose preparation of opposing (for example treatment or prevention) dehydration or (B) can prepare the application that (for example solvable at water) becomes to be used for the medicine of the 25-135mM galactose preparation that opposing (for example treatment or prevention) dewaters in preparation (A).
In the preferred embodiment that the present invention uses, 25-135mM aqueous galactose preparation defines as above.
In the preferred embodiment that the present invention uses, medicine is a compositions as defined above.
In preferred embodiments, the invention provides galactose and source of sodium ions is used for resisting dehydration at preparation (A) 25-135mM and with the aqueous galactose preparation of relevant shortage or (B) can be mixed with 25-135mM and be used to resist and dewaters and the medicine of the aqueous galactose preparation of relevant shortage is used.Relevant shortage can be the mineral losses, electrolyte imbalance etc.
In preferred embodiments, the invention provides galactose and source of sodium ions is used for resisting the aqueous galactose preparation of child (for example baby) dehydration or (B) can be mixed with the application of medicine that 25-135mM is used to resist the aqueous galactose preparation of child (for example baby) dehydration at preparation (A) 25-135mM.
The relevant shortage with (when existing) of preferred dehydration is a symptom of diarrhea.Diarrhoea can be (for example) enterotoxin effect (for example typically the cholera in the third world), the result of have a rest behind virus function (for example typically the rotavirus in developed world) or the surgical operation (for example when GI have a rest when important).Can make every kind of component concentrations be fit to the optimization treatment by slightly, the dehydration that moderate or serious diarrhoea cause and the requirement of relevant shortage.In order to resist dehydration, preferred higher sodium and chloride concentration as serious symptom of diarrhea.Alternatively, the situation that can cause dewatering can be self-induced (for example passing through alcohol consumption).
In the preferred embodiment that the present invention uses, dehydration or relevant shortage are life-threatening.
From also having on the other hand, the invention provides opposing experimenter dehydration method, it comprises step: aqueous formulation as defined above from effective dose to the experimenter that use.
From still having on the other hand, the invention provides the method that is used to resist experimenter's dehydration and relevant shortage, it comprises step: aqueous formulation as defined above from effective dose to the experimenter that use.
Although the experimenter can be any age, preferred experimenter is child (for example baby).The preferred dehydration shortage relevant with (when existing) is the symptom of diarrhoea (for example seriously suffering from diarrhoea).Diarrhoea can be (for example) enterotoxin effect (for example typically the cholera in the third world), the result of have a rest behind virus function (for example typically the rotavirus in developed world) or the surgical operation (for example when GI have a rest when important).Alternatively, the situation that can cause dewatering can be self-induced (for example passing through alcohol consumption).
On nonrestrictive meaning, the present invention is described now with reference to the following example.
Embodiment
The aqueous formulation A of 9 kinds of reformulations of preparation, A1 and B-H, it has composition and the concentration after reformulating as shown in table 1 in water:
Table 1
| Material | Concentration mM | |||||||
| ??A(A1) | ??B | ????C | ??D | ??E | ??F | ??G | ??H | |
| Galactose | ??45(90) | ??60 | ????80 | ??40 | ??45 | ??45 | ??75 | ??55 |
| Glucose | ??45(0) | ??60 | ????80 | ??40 | ??45 | ??45 | ??75 | ??55 |
| Sodium chloride | ??45 | ??70 | ????25 | ??30 | ??35 | ??20 | ??25 | ??60 |
| Potassium chloride | ??25 | ??20 | ????20 | ??15 | ??20 | ??25 | ??20 | ??20 |
| Trisodium citrate/citric acid | ??10 | ??10 | ????10 | ??10 | ??15 | ??13.3/ ??6.7 | ??0 | ??10 |
| Sucrose | ???0 | ???0 | ????0 | ??80 | ??20 | ??0 | ??0 | ??0 |
| Fructose | ???0 | ???0 | ????0 | ??1 | ??2 | ??0 | ??0 | ??0 |
| Sodium bicarbonate | ???0 | ???0 | ????0 | ??0 | ??0 | ??0 | ??15 | ??0 |
Acquisition specific concentrations when the solid mixture of the preparation component of weighing in advance will a certainly be partially soluble in the water of designated volume with box lunch.The unit volume that adds the water of reformulating compositions can be up to 1000ml.Typically 250ml will be suitable, and single dose can be by 1 that uses in appropriate intervals, 2 or 3 250ml unit volumes compositions.Can use Fructus Citri Limoniae as required, Citrus aurantium Linn., Ribes fasciculatum Var Chincsis Maxim, Fructus Citri tangerinae, mandarin orange or raspberry become good to eat with every kind of aqueous formulation seasoning.
For composition F, G and H, na concn are respectively 60,40 and 90mM, and chloride concentration is respectively 45,45 and 80mM.Higher sodium and chloride concentration are ideal for cacatory effective treatment.Therefore, composition F, G and H are respectively in moderate, and be effective in the slight and cacatory treatment.
General preparation I, J, K, L, M and N represent in table 2.
Table 2
| Material | Concentration mM | |||||
| ??I | ????J | ????K | ????L | ????M | ????N | |
| Galactose | ??120 | ????120 | ????60 | ????60 | ????60 | ????60 |
| Glucose | ??- | ????- | ????60 | ????60 | ????- | ????- |
| Sodium chloride | ??60 | ????30 | ????60 | ????30 | ????60 | ????30 |
| Potassium chloride | ??20 | ????20 | ????20 | ????20 | ????20 | ????20 |
| Trisodium citrate/citric acid | ??- | ????13.3/6.7 | ????- | ????13.3/6.7 | ?????- | ????13.3/6.7 |
| Maltodextrin (chain 6) | ??0 | ????0 | ????0 | ????0 | ????10 | ????10 |
Claims (34)
1. aqueous formulation that is used to resist dehydration, it comprises the galactose that concentration is 25-135mM, source of sodium ions and water.
2. as desired aqueous formulation in claim 1, the galactose concentration in the wherein said aqueous formulation is 25-130mM.
3. as desired aqueous formulation in claim 1 or 2, the galactose concentration in the wherein said aqueous formulation is 37-120mM.
4. as desired aqueous formulation in arbitrary aforementioned claim, the galactose concentration in the wherein said aqueous formulation is 40-120mM.
5. desired aqueous formulation as in arbitrary aforementioned claim, wherein said source of sodium ions are randomly with the sodium chloride of sodium citrate.
6. as desired aqueous formulation in arbitrary aforementioned claim, the Na ion concentration in the wherein said aqueous formulation is 25-100mM.
7. as desired aqueous formulation in arbitrary aforementioned claim, the Na ion concentration in the wherein said aqueous formulation is 30-90mM.
8. as desired aqueous formulation in arbitrary aforementioned claim, the Na ion concentration in the wherein said aqueous formulation is 35-90mM.
9. as desired aqueous formulation in arbitrary aforementioned claim, the Na ion concentration in the wherein said aqueous formulation is 45-90mM.
10. as desired aqueous formulation in arbitrary aforementioned claim, the Na ion concentration in the wherein said aqueous formulation is 60-90mM.
11. as desired aqueous formulation in arbitrary aforementioned claim, it comprises potassium ion source in addition, the concentration of described potassium ion source in described aqueous formulation is 20-25mM.
12. as in arbitrary aforementioned claim desired aqueous formulation, it comprises one or more other glucose, sucrose, dextrose, fructose, sugar of lactose and maltose of being selected from addition.
13. as desired aqueous formulation in arbitrary aforementioned claim, wherein Tang total concentration is 50-300mM.
14. as desired aqueous formulation in arbitrary aforementioned claim, the total concentration of wherein said sugar is 50-200mM.
15. as desired aqueous formulation in arbitrary aforementioned claim, the total concentration of wherein said sugar is 55-175mM.
16. as desired aqueous formulation in arbitrary aforementioned claim, the total concentration of wherein said sugar is 60-135mM.
17. as desired aqueous formulation in arbitrary aforementioned claim, the total concentration of wherein said sugar is 90-130mM.
18. as each desired aqueous formulation among the claim 12-17, wherein galactose and glucose are to exist with the total amount that is enough to satisfy the sugared needs of sodium co-transport in effective rehydration, and the molar concentration rate of galactose and glucose is 0.6: 1-1: 0.6.
19. as the desired aqueous formulation of claim 18, the molar concentration rate of wherein said galactose and glucose is 0.8: 1-1: 0.8.
20. as claim 18 or 19 desired aqueous formulations, the molar concentration rate of wherein said galactose and glucose is 0.9: 1-1: 0.9.
21. as each desired aqueous formulation among the claim 18-20, the molar concentration rate of wherein said galactose and glucose is about 1: 1.
22. as each desired aqueous formulation in the claim 12 to 21, the concentration of glucose in the wherein said aqueous formulation is 30-135mM.
23. as each desired aqueous formulation in the claim 12 to 22, the concentration of glucose in the wherein said aqueous formulation is 35-130mM.
24. as each desired aqueous formulation in the claim 12 to 23, the concentration of glucose in the wherein said aqueous formulation is 37-120mM.
25. as each desired aqueous formulation in the claim 12 to 24, the concentration of glucose in the wherein said aqueous formulation is 40-100mM.
26. as each desired aqueous formulation in the claim 12 to 25, the concentration of glucose in the wherein said aqueous formulation is 45-80mM.
27. as desired aqueous formulation in arbitrary aforementioned claim, wherein the concentration of glucose to small part is satisfied by the glucoside oligosaccharide.
28. as the desired aqueous formulation of claim 27, wherein said glucoside oligosaccharide is a maltodextrin.
29. can prepare the compositions that forms as the defined aqueous formulation of arbitrary aforementioned claim for one kind in water, described compositions comprises galactose, source of sodium ions, randomly other sugar and randomly other ion source.
30. galactose and source of sodium ions are used for resisting the galactose aqueous formulation of dehydration or (B) can be mixed with the application of medicine that 25-135mM is used to resist the galactose preparation of dehydration at preparation (A) 25-135mM.
31., be used for preparation (A) 25-135mM and be used to resist the galactose aqueous formulation of child's dehydration or (B) can be mixed with the medicine that 25-135mM is used to resist the galactose aqueous formulation of child's dehydration as the application of desired galactose of claim 30 and source of sodium ions.
32. as claim 30 or 31 desired application, wherein said dehydration is the diarrheal symptom.
33. one kind is used to resist experimenter's dehydration method, it comprises following steps: to the experimenter use effective dose as claim 1-28 in each defined aqueous formulation.
34. as the desired method of claim 33, wherein said experimenter is the child.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0126746.7 | 2001-11-07 | ||
| GBGB0126746.7A GB0126746D0 (en) | 2001-11-07 | 2001-11-07 | Rehydrating formulation |
| US34075101P | 2001-11-30 | 2001-11-30 | |
| US60/340,751 | 2001-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1582157A true CN1582157A (en) | 2005-02-16 |
Family
ID=9925340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA028220102A Pending CN1582157A (en) | 2001-11-07 | 2002-11-04 | Rehydrating formulation |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1441741A1 (en) |
| JP (1) | JP2005508984A (en) |
| CN (1) | CN1582157A (en) |
| AP (1) | AP2004003051A0 (en) |
| BR (1) | BR0213942A (en) |
| CA (1) | CA2466278A1 (en) |
| EA (1) | EA200400636A1 (en) |
| GB (1) | GB0126746D0 (en) |
| MX (1) | MXPA04004339A (en) |
| OA (1) | OA13061A (en) |
| ZA (1) | ZA200403278B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108777978A (en) * | 2016-03-04 | 2018-11-09 | 鹫尾伸人 | Beverage product and method and apparatus for manufacturing beverage product |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016104671A1 (en) * | 2014-12-26 | 2016-06-30 | 株式会社明治 | Replenisher containing dietary fiber |
-
2001
- 2001-11-07 GB GBGB0126746.7A patent/GB0126746D0/en not_active Ceased
-
2002
- 2002-11-04 EP EP02779653A patent/EP1441741A1/en not_active Withdrawn
- 2002-11-04 JP JP2003541847A patent/JP2005508984A/en active Pending
- 2002-11-04 AP APAP/P/2004/003051A patent/AP2004003051A0/en unknown
- 2002-11-04 OA OA1200400128A patent/OA13061A/en unknown
- 2002-11-04 EA EA200400636A patent/EA200400636A1/en unknown
- 2002-11-04 MX MXPA04004339A patent/MXPA04004339A/en unknown
- 2002-11-04 CN CNA028220102A patent/CN1582157A/en active Pending
- 2002-11-04 CA CA002466278A patent/CA2466278A1/en not_active Abandoned
- 2002-11-04 BR BR0213942-1A patent/BR0213942A/en not_active Application Discontinuation
-
2004
- 2004-04-30 ZA ZA200403278A patent/ZA200403278B/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108777978A (en) * | 2016-03-04 | 2018-11-09 | 鹫尾伸人 | Beverage product and method and apparatus for manufacturing beverage product |
| US10869492B2 (en) | 2016-03-04 | 2020-12-22 | Nobuto Washio | Beverage product and method and apparatus for producing beverage product |
Also Published As
| Publication number | Publication date |
|---|---|
| EA200400636A1 (en) | 2004-12-30 |
| BR0213942A (en) | 2004-09-08 |
| MXPA04004339A (en) | 2005-05-16 |
| JP2005508984A (en) | 2005-04-07 |
| CA2466278A1 (en) | 2003-05-15 |
| EP1441741A1 (en) | 2004-08-04 |
| GB0126746D0 (en) | 2002-01-02 |
| ZA200403278B (en) | 2005-01-12 |
| AP2004003051A0 (en) | 2004-06-30 |
| OA13061A (en) | 2006-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1512845A (en) | Calorically dense liquid oral supplement | |
| AU2004317895B2 (en) | Dietary supplement and method for treating digestive system-related disorders | |
| CN101036515A (en) | Physical recovery healthy food and preparation process thereof | |
| CN1318371A (en) | New use of flavone | |
| CN102423487B (en) | Osteoarticular health-care composition and its application | |
| IL178049A (en) | Dietary supplement for the treatment and prevention of digestive system and digestive system-related disorders comprising a lipid supplement, a soluble fiber and at least one amino acid | |
| EP1351584A2 (en) | Nutritional composition for a bone condition | |
| CN107375221A (en) | One kind contains farnoquinone calcium tablet and preparation method thereof | |
| CN1133379C (en) | Isotonic sports beverage and its preparing process | |
| CN1582157A (en) | Rehydrating formulation | |
| US20040086576A1 (en) | Ergogenic multivitamin-mineral energy supplement for the prevention of muscle fatigue | |
| CN103238841A (en) | Food composition containing Maca and saussurea involucrata culture and application thereof | |
| KR102666724B1 (en) | Composition containing inositol phosphate | |
| KR101905863B1 (en) | Pharmaceutical Composition for Preventing or Treating of Inflammatory Diseases and Metabolic Diseases Comprising hyaluronic acid Nanoparticles | |
| US20030134804A1 (en) | Rehydrating formulation | |
| KR101729137B1 (en) | Composition for Reducing Fatigue containing Chito-oligosaccharide | |
| CN1589786A (en) | Composite effervescent preparation containing soya isoflavone | |
| WO2003039556A1 (en) | Rehydrating formulation | |
| JP2004166616A (en) | Health food | |
| CN109393487A (en) | A kind of sweet chili sauce is syrup dedicated and preparation method thereof | |
| AU2002342995A1 (en) | Rehydrating formulation | |
| CN1596727A (en) | Functional composite sugar and its production method | |
| CN117715540A (en) | Infant formula for feeding infants receiving infant formula and human breast milk | |
| CN105685737A (en) | Sports beverage with low blood sugar index and preparing and using methods thereof | |
| CN116831085A (en) | Method for reducing arsenic absorption and accumulation of mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |